Active substances
Cetrimide + Lidocaine
- SFDA 2
- Health Canada 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| XYLONOR SPRAY | 15,0.15 %,% | Spray · Nasal use | 36 Inhaler | SAR 22.60 | NCE · Prescription | SEPTODENT | Valid |
| LIGNOSOL AEROSOL | 10, 0.7, 29.7 % | Solution for spray · Topical | 1 Pressurised container | SAR 16.10 | Generic · Prescription | ARAB CENTER FOR PHARMACEUTICALS & CHEMICAL IND. CO. | Withdrawn by regulatory authority · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| XYLONOR | 02218607 | 15 G / 100 G; 150 MG / 100 G | SPRAY (METERED-DOSE) · BUCCAL | SEPTODONT |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.